Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is
associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …

Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of
approximately 80%. Tamoxifen treatment of the first cancer has been associated with a …

Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of∼ 80%,
and following the first diagnosis the10‐year risk of contralateral breast cancer is∼ 30%. It …

Purpose Chemoprevention with a selective estrogen receptor modulator (tamoxifen or
raloxifene) is a non-surgical option offered to high-risk women to reduce the risk of breast …

Background Women with a mutation in BRCA1 or BRCA2 have a high risk of developing
breast cancer and of contralateral cancer after the initial diagnosis of breast cancer …

Given the greatly elevated risks of contralateral breast cancer (CBC) observed in breast
cancer patients who carry mutations in BRCA1 and BRCA2, it is critical to determine the …

ContextAmong cancer-free women aged 35 years or older, tamoxifen reduced the incidence
of estrogen receptor (ER)–positive but not ER-negative breast cancer. The effect of …

The purpose of our study was to review the evidence for the efficacy of surveillance for early
detection, bilateral prophylactic mastectomy, prophylactic oophorectomy and …

Purpose To estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers
after diagnosis and to determine which factors are predictive of the risk of a second primary …

BRCA1 and BRCA2 mutation carriers have an increased risk of contralateral breast cancer
after primary breast cancer. Risk reduction strategies are discussed after assessment of risk …